The pharmaceutical company Laboratorios Rubió, a member of CataloniaBio &  HealthTech, has closed the acquisition of the Spanish company Fisiopharma,  which will allow them to diversify beyond prescription products and enter the  nutraceutical segment. The company did not disclose the figures of the operation.

Acquiring Fisiopharma, Laboratorios Rubió strengthens the line of food supplements, with various products aimed at neuropathies of the central nervous system and muscle and joint tissue. "Fisiopharma products complement many of our medicines as they act on the same therapeutic areas, so we are convinced that we will generate synergies, both in prevention and treatment, which will meet the needs of patients," he said. valued Pelayo  Rubió, CEO of Laboratorios Rubió.

Rubió closed last year with a turnover of 54 million euros, an increase of 10%. This 2021 has also been the first in which it has marketed the first products in the United States. According to the pharmaceutical company, this year the company expects to close with a revenue of 73 million euros; by 2022, the goal is to reach 92 million euros in sales.